In today’s ACT Brief, we explore how Bayesian trial designs are gaining traction in rare disease research, what priorities clinical operations leaders should focus on in 2026, and how rare disease ...

As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...

Jonathan Andrus, co-CEO of CRIO, discusses how increased reliance on site-based technologies and eSource is strengthening ...

Jonathan Andrus, co-CEO of CRIO, explains how protocol-driven eSource templates and standardized data capture are improving consistency, oversight, and efficiency across clinical trial sites.

Andrus: The biggest risk is fragmented, disconnected data collection across sites. If you think about a large phase 3 trial ...

In today’s ACT Brief, we examine how site-level data capture is becoming central to trial execution, how Merck and Mayo ...

In today’s ACT Brief, we examine how protocol-driven eSource is reshaping data capture at sites, how digital protocols and ...

Mayo Clinic, for its part, described the collaboration as its first strategic partnership of this scale with a global ...

Angela Zubel, chief development officer, Debiopharm, explains how AI-enabled site selection, patient allocation, and real-time data monitoring can reduce costs, shorten timelines, and limit ...

In today’s ACT Brief, we examine how SCOPE 2026 reinforced the link between speed and strategy, how AI adoption is driving ...

As clinical development grows more complex, sponsors are rethinking how outsourcing models, technology, and partnerships align to support both speed and sustainability. The shift toward hybrid models, ...

In today’s ACT Brief, we examine how predictive analytics are shaping portfolio decisions, how industry collaboration is ...